A phase II study to assess the efficacy and safety of the CD30/CD16A-bispecific antibody AFM13 in patients with CD30-positive PTCL is ongoing [93]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.